肺纤维化患者FVC下降可作为死亡替代终点
该研究汇总尼达尼布试验中2583例肺纤维化患者数据,采用联合模型分析52周内FVC占预计值百分比下降与死亡时间的关联。结果显示FVC下降速率越快、当前值越低,死亡风险越高,支持FVC下降作为死亡替代终点。
要点
- FVC占预计值每下降5个百分点,死亡风险显著增加。
- FVC下降速率与死亡风险的关联在IPF和其他ILDs中一致。
- FVC下降可作为肺纤维化患者死亡替代终点。
核心结论
- 肺纤维化患者52周内FVC占预计值百分比下降与死亡风险显著相关,支持其作为死亡替代终点。
研究设计与样本
- 汇总尼达尼布和安慰剂组试验数据,纳入特发性肺纤维化、其他进展性肺纤维化和系统性硬化相关肺纤维化患者,共2583例。
- 采用纵向和时间事件数据的联合模型,评估52周内FVC占预计值百分比下降与死亡时间的关联。
主要发现
- FVC占预计值百分比下降速率每增加5个百分点,死亡风险HR为1.79(95%CI:1.57,2.03)。
- 当前FVC占预计值百分比每降低5个百分点,死亡风险HR为1.24(95%CI:1.17,1.32)。
- FVC下降速率与死亡风险的关联在IPF和其他ILDs患者中一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Surrogate endpoints enable determination of meaningful treatment effects more efficiently than applying the endpoint of ultimate interest. We used data from trials of nintedanib in subjects with pulmonary fibrosis to assess decline in forced vital capacity (FVC) as a surrogate for mortality. METHODS: Data from the nintedanib and placebo groups of trials in subjects with idiopathic pulmonary fibrosis, other forms of progressive pulmonary fibrosis, and pulmonary fibrosis due to systemic sclerosis (NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02999178, NCT02597933) were pooled. Using joint models for longitudinal and time-to-event data, we assessed the association between decline in FVC % predicted and time to death over 52 weeks. The rate of change in FVC % predicted and the current value of FVC % predicted were modelled longitudinally and estimates applied as predictors in time-to-event models. RESULTS: Among 2583 subjects with pulmonary fibrosis, both a greater rate of decline in FVC % predicted and a lower current value of FVC % predicted were associated with an increased risk of death over 52 weeks (HR 1.79 [95% CI: 1.57, 2.03] and HR 1.24 [1.17, 1.32] per 5-percentage point decrease, respectively). Associations between the rate of change in FVC % predicted and the risk of death were consistent between patients with IPF and other ILDs. CONCLUSION: Data from clinical trials in subjects with pulmonary fibrosis of diverse aetiology demonstrate a strong association between decline in FVC % predicted and mortality over 52 weeks, supporting FVC decline as a surrogate for mortality in these patients.
引用
- Maher TM, Stowasser S, Voss F, et al. Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis. Respirology. 2023. PMID: 37646126. doi:10.1111/resp.14579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。